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Intracrine factorPituitary adenylate cyclase-activating polypeptide (PACAP), a hypophysiotropic neurohormone, participates
in the regulation of pleiotropic functions. The recent discovery of intracellular PACAP receptors in the brain
and the testis as well as the physico-chemical characteristics of PACAP, i.e. extended α-helix containing
basic residues, prompted us to evaluate the propensity of PACAP to cross the plasma membrane in a
receptor-independent manner. Using confocal microscopy and ﬂow cytometry, we demonstrated the ability
of FITC-conjugated PACAP to efﬁciently penetrate into the internal cell compartment by direct translocation
and endocytosis through clathrin-coated pits and macropinocytosis. Our study also revealed that, once inside
the cells, PACAP38 is not entirely degraded by intracellular enzymes and that a signiﬁcant amount of intact
PACAP38 is also able to exit cells. Moreover, using binding assay on rat nuclear fractions from various tissues,
PACAP nuclear receptors were identiﬁed. We also found that PACAP stimulates calcium release in rat testis
nuclei. Interestingly, PACAP27 and PACAP38 but not VIP were able to upregulate de novo DNA synthesis in
testis nuclei and that this effect was abolished by PACAP(6–38). These results support the presence of
PAC1 receptors at the nuclear membrane and raise questions about their role in the biological activity of
the peptide. These ﬁndings contribute to the characterization of PACAP as an intracrine factor and suggest
that these intracellular PAC1 binding sites, probably associated with speciﬁc biological activities, should be
taken into account during the development of PACAP-based drugs.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Pituitary adenylate cyclase-activating polypeptide, a 38-amino acid
C-terminally α-amidated neuropeptide (PACAP38), was originally iso-
lated fromovine hypothalamic extracts on the basis of its ability to stim-
ulate cyclic adenosinemono-phosphate (cAMP) production in cultured
rat anterior pituitary cells [1]. Later, an equiactive C-terminally truncat-
ed form, derived from the internal cleavage of PACAP38 (Gly28–Lys29–
Arg30), was isolated and named PACAP27 [2]. These two biologically
active peptides have been almost totally conserved during evolution,, benzotriazole-1-yl-oxy-tris-
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l rights reserved.from ﬁsh to mammals [3]. Only the positively charged C-terminal
extension, i.e. PACAP(28–38), which is not essential for the biological
activity of the peptide, is slightly variable [3]. The fact that evolutionary
pressure has acted to strongly preserve the primary sequence of the N-
terminal domain of PACAP supports the notion that this region is essen-
tial for biological activity. PACAP27 shares 68% amino acid sequence
homology with vasoactive intestinal polypeptide (VIP), identifying
PACAP as a member of the VIP/glucagon/growth hormone-releasing
hormone super-family [4]. PACAP isoforms are widely distributed in
the central nervous system and in peripheral tissues [3]. However,
radioimmunoassay analysis revealed differences between PACAP38
and PACAP27 in terms of abundance. For instance, in the central ner-
vous system, the adrenal gland and the testis, PACAP38 is the predom-
inantmolecular form [3]. Noteworthy, the total amount of PACAP in the
testis is higher than in thewhole brain [5], supporting an important role
of this peptide in reproduction. PACAP isoforms exert pleiotropic
activities, including functions as a hypophysiotropic hormone, neuro-
modulator, and neurotrophic factor [3,6], all mediated through the acti-
vation of two receptor types that are widely distributed in the central
nervous system and in peripheral tissues [3]. Type I binding sites,
named PAC1, exhibit a high afﬁnity and speciﬁcity to PACAP whereas
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afﬁnity for PACAP and VIP.
The presence of nuclear VIP and PACAP receptors, as demonstrat-
ed in testicular germ cells [7], human breast cancer cells [8] and
human colonic adenocarcinoma cells [9], has raised the possibility
that PACAP could act as an intracrine factor. For instance, it has
been reported that higher levels of PACAP binding sites, and more
particularly PAC1 receptor-like immunoreactivity, are found in cyto-
solic and nuclear spermatid enriched-fractions while such binding
sites are virtually absent in membrane extracts [7]. Interestingly,
addition of PACAP to cytosolic preparations of spermatids markedly
stimulated the expression and activation of ERK-type mitogen-
activated protein kinase, supporting the concept of an intracrine
mode of action [7]. Receptor-mediated endocytosis could be per-
ceived as a possible way for PACAP to translocate into the internal
cell compartment in order to activate these putative binding sites.
However, based on its propensity to interact with cell membranes
[10], its amphipatic character, and the numerous basic residues dis-
persed throughout its C-terminal helical domain [11], it is highly con-
ceivable that PACAP could cross the plasma membrane in a receptor-
independent manner, as observed with human calcitonin, a peptide
belonging to the same family [12]. Consistent with this hypothesis,
PACAP possesses structural and physico-chemical characteristics
often found in amphiphilic alpha-helical antimicrobial peptides and
cell-penetrating peptides (CPPs). Besides, those characteristics were
found to be responsible for the ability of such derivatives to cross
cell membranes in a receptor-independent mechanism [13].
Our present investigation brings new insights regarding the inter-
nalization and molecular trafﬁcking of the neuropeptide PACAP. We
show, for the ﬁrst time, the propensity of both FITC-labeled PACAP
isoforms to reach the internal cell compartment by a receptor-
independent mechanism involving direct translocation and endocy-
tosis. Moreover, we observe the presence of PACAP binding sites in
nuclear fractions of various rat tissues and demonstrate the function-
ality of PACAP receptors on isolated testis nuclei through calcium
mobilization and transcription initiation assays. Altogether, these
results support and complement the intracrine role of PACAP in several
tissues and raise the possibility that some PACAP-mediated actions
could be associated with the activation of these nuclear receptors.
2. Experimental procedures
2.1. Materials
Fmoc-protected amino acids, Rink-amide AM-functionalized poly-
styrene resin and BOP (benzotriazol-1-yl-oxy-tris(dimethylamino)-
phosphonium hexaﬂuorophosphate) reagent were purchased from
Chem-Impex (Wood Dale, IL, USA). Common solvents for solid
phase peptide synthesis and puriﬁcation were obtained from Fisher
Scientiﬁc (Nepean, ON, Canada) and triﬂuoroacetic acid (TFA) was
from PSIG (Montreal, QC, Canada). Isotope Na125I was purchased from
PerkinElmer (Montreal, QC, Canada). Anti-fade reagent (ProLong),
Fluo-4AM, FuraRed AM, AlexaFluor 568-conjugated streptavidin
(Strep) and dNTPs were supplied by Invitrogen (Burlington, ON,
Canada). DRAQ5™ nuclear staining reagent was from BioSatus Ltd.
(Leicestershire, UK). Nucleoporin 62, Caveolin-3 and Cytochrome C
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Endocytosis inhibitors and other chemicals including
ﬂuorescein isothiocyanate (FITC), biotin, and propidium iodide (PI)
were ordered from Sigma Aldrich (Mississauga, ON, Canada).
2.2. Peptides
All peptides were synthesized on a Rink-amide AM-functionalized
polystyrene resin (0.53 mmol/g) using standard Fmoc chemistry and
a BOP coupling strategy. Biotinylated peptides were directly obtainedby coupling a biotin moiety to the N-terminus of the peptide-resins.
For FITC-conjugated peptides, Fmoc-Ahx-OH was ﬁrst coupled at the
N-terminus of each peptidyl-resin to avoid a known side reaction
[14]. Following Fmoc removal, a solution containing FITC (1.2 eq.),
triethylamine (20 eq.) in DMF/DCM (1:1) was added and coupling
of the ﬂuorescent dye was performed overnight. Peptide cleavage
was achieved using a mixture of TFA/ethanedithiol/phenol/water
(92/2.5/3/2.5) for 3 h and the resulting crude peptides, precipitated
with diethyl ether, were puriﬁed on a preparative RP-HPLC using a
Phenomenex C18 Gemini column. Collected fractions were analyzed
concomitantly by analytical RP-HPLC, performed on a Phenomenex Jupi-
ter C18 column, and MALDI-TOF mass spectrometry using α-cyano-4-
hydroxycinnamic acid as matrix (Voyager DE, Applied Biosystems).
Fractions corresponding to the desired product with purity higher
than 95% were ﬁnally pooled and lyophilized.
2.3. Cell culture
CHO-K1 and HEK-293 cells were maintained respectively in Ham-
F12 and DMEM medium supplemented with 2 mM L-glutamine,
100 UI/mL each of penicillin and streptomycin, and 10% fetal bovine
serum (FBS). HeLa cells were grown in MEM media containing 10%
fetal bovine serum, 100 UI/mL each of penicillin and streptomycin,
2 mM L-glutamine, and 1 mM sodium pyruvate. These cell lines do
not express the PACAP receptors. Cells were maintained as a mono-
layer at 37 °C in a humidiﬁed atmosphere of 5% CO2 and 95% air and
passaged by trypsinization once cells reached 70–80% conﬂuence.
2.4. Confocal microscopy
Cells, grown in an 8-well chamber slide (Lab-Tek, Nalge Nunc
International, Rochester, NY, USA), 50,000 cells/well, were incubated
in HEPES–Krebs–Ringer (HKR) buffer (5 mM HEPES, 137 mM NaCl,
2.68 mM KCl, 2.05 mM MgCl2·6H2O, 1.8 mM CaCl2·2H2O and 1 g/L
glucose, pH 7.4) containing the ﬂuorescent peptide (10−6 M, 37 °C)
for 1 h. Following careful washes with phosphate-buffered saline
(PBS), an acidic buffer containing 0.2 M glycine and 0.1 M NaCl (pH
4) and ﬁnally PBS, cell nuclei were stained with DRAQ5™ (5 μM) for
10 min. After washing with PBS, the subcellular localization of FITC-
conjugated PACAP27 and PACAP38 was directly analyzed, using PBS
as mounting solution, with a Nikon Plan Apo 100 objective on a
Nikon Eclipse E800 microscope (Nikon, Melville, NY, USA) equipped
with a Bio-Rad Radiance 2000 confocal imaging system (Bio-Rad
Laboratories, Hercules, CA, USA).
2.5. Flow cytometry
Cells seeded in 12-well plates were incubated with ﬂuorescent
peptides (10−6 M) for 1 h at 37 °C in HKR buffer. Cells were washed
several times by PBS and acidic buffer, then, enzymatically lysed
with trypsin/EDTA (5 min at 37 °C) and the reaction was stopped by
the addition of FBS (10% in PBS). Following centrifugation (5 min at
1000×g), pelleted cells were resuspended in 500 μL of PBS containing
PI (0.5 μg/mL) and kept on ice until measurement. A minimum of
10,000 cells per sample were then analyzed on a FACScan (BD Biosci-
ences, San Jose, CA, USA). PI positive cells were excluded from the
analysis and the mean ﬂuorescence intensity (MFI) of the living cell
population was used for statistical analysis. Data interpretation was
performed with WinMDI software (Windows Multiple Document In-
terface for Flow Cytometry).
2.6. Mechanism of PACAP cellular uptake
Cellular uptake mechanism of FITC-conjugated PACAP27 and
PACAP38 was assessed by using inhibitors targeting speciﬁc endocy-
tosis pathways. Endocytosis inhibitors such as nocodazole (20 μM),
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(10 μg/mL), and amiloride (2.5 mM) were added to CHO-K1 cells
30 min before treatment with FITC-labeled peptides (10−6 M).
Other inhibitors such as NH4Cl (10 mM), chloroquine (50 μM), malei-
mide (10 μM), and methyl-β-cyclodextrin (MβCD, 5 mM), were in-
troduced into the culture medium (without FBS) 10 min prior to the
addition of the FITC-conjugated peptide (10−6 M). Inﬂuence of the
temperature on the cellular uptake was evaluated by incubating
CHO-K1 cells, pre-cooled to 4 °C in serum-free medium for 15 min,
with ﬂuorescent peptides (10−6 M) for 1 h at 4 °C. Noteworthy, all
solutions were also cooled to 4 °C before use. To deplete cellular
ATP, cells were incubated with 10 mM sodium azide in the presence
of 6 mM 2-deoxy-D-glucose in HKR buffer without MgCl2 for 1 h.
Following washes with PBS and acidic buffer as described above,
cellular uptake was evaluated by ﬂow cytometry and the subcellular
localization of the peptide was analyzed by confocal microscopy
using PBS as mounting solution.
2.7. Peptide iodination
Ac-PACAP27 and Ac-PACAP38 were radiolabeled with 0.5 mCi
Na125I by the chloramine-T technique as previously described [15].
Iodinated peptides were puriﬁed using a C18 Sep-Pak cartridge
(Waters Corp., Milford, MA, USA), collected and stored at −20 °C
until use.
2.8. Cellular uptake studies at physiological concentration
Cellular uptake kinetics were investigated by incubating CHO-K1
cells (2.5×105 cells/well) in FBS-freemediawith radiolabeled peptides,
i.e. 125I-Ac-PACAP27 and 125I-Ac-PACAP38 (0.05 nM), for various
periods of time at 37 °C. Internalization was stopped by ice-cold PBS
and acid buffer (pH 4) washings. Cells were then lysed with NaOH
(0.1 M), and the radioactivity was quantiﬁed using a γ-counter.
Membrane-bound radioactivity was evaluated by incubating CHO-K1
cells with radiolabeled peptides for 30 s.
The ability of radiolabeled peptides to exit cells once internalized
was studied with living CHO-K1 cells grown on 6-well plates (5×105
cells/well). Cells were ﬁrst incubated in FBS-free media containing
125I-Ac-PACAP27 or 125I-Ac-PACAP38 (0.05 nM) for 1 h to ensure the
PACAP isoforms cellular uptake, and washed three times with ice-cold
FBS-free media, acid buffer and then ice-cold FBS-free media, respec-
tively, to remove attachment and membrane-bond radiolabeled pep-
tide. Then, 1 mL of FBS-free medium was added. At various periods of
time, 100 μL of mediumwas taken out and radioactivity was quantiﬁed
using a γ-counter. Percentage of residual intracellular radioactivity was
calculated based on the following equation:
%RR ¼
R− Ri 10−ið Þ þ∑ii¼1Ri
h i
R
 100
Where % RR is the percentage of residual intracellular radioactivity
at each time point, R is the total initial speciﬁc radioactivity, which is
obtained by subtracting the cell-bound radioactivity after 30 s of
incubation from the total counts used in each cell well, Ri is the mea-
sured radioactivity in the 100 μL medium sample taken at a speciﬁc
time point, and i values correspond to sequential numbers of each
time point sample withdrawal.
2.9. Peptide metabolism analysis
Integrity of PACAP isoforms following their exit from the cytoplasm
was studied as follows. CHO-K1 cells maintained in 175 cm2 cell culture
ﬂasks were harvested and re-suspended (2×106 cells/mL) in FBS-
free medium containing PACAP27 or PACAP38 (10−5 M) for 30 min.Membrane-bound peptides were fragmented by an ice-cold trypsiniza-
tion treatment (5 min) and removed by two acid buffer (pH 4) washes
followed by a PBS wash. Cells were then re-suspended in FBS-free me-
dium for an additional 30 min. The suspension was centrifuged at 4 °C
for 5 min at 1500×g. Salts from the supernatant were eliminated by
reverse-phase puriﬁcation using a Sep-Pak C18 cartridge and the pep-
tide mixture was then eluted with 60% ACN in H2O (0.1% TFA) (Waters
Corporation, Milford, MA). Eluted material was ﬁnally characterized
by analytical RP-HPLC and MALDI-TOF mass spectrometry using 2,5-
dihydroxybenzoic acid as matrix.
2.10. Nuclei isolation
Male Sprague Dawley rats (200–250 g) were obtained from
Charles River (St-Constant, QC, Canada). Rat tissues were homoge-
nized and incubated for 15 min in buffer (10 mM Tris–HCl (pH 7.4),
3 mM MgCl2, 10 mM NaCl) supplemented with the Sigma protease
inhibitor cocktail. Following the removal of non-homogenized tissues
by slow centrifugation (1,000×g, 1 min), supernatants were then
centrifuged (600×g) for 15 min at 4 °C. Resulting pellets were re-
suspended in lysis buffer (10 mM Tris–HCl (pH 7.4), 3 mM MgCl2,
10 mM NaCl, 0.5% (v/v) Igepal CA-630, 1 mM DTT, 1 mM phenyl-
methylsulfonyl ﬂuoride (PMSF)), supplemented with the Sigma pro-
tease inhibitor cocktail, and incubated on ice for 15 min before
being centrifuged (600×g) for 15 min. Resulting pellets were once
again suspended in lysis buffer with added Igepal (1%) and incubated
on ice for another 15 min. The ﬁnal pellets, obtained by a 15-min cen-
trifugation at 600×g and containing the nuclei, were re-suspended in
20 mM Na-HEPES (pH 7.9) containing 25% (v/v) glycerol, 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.2 mM EGTA, 0.5 mM PMSF,
0.5 mM DTT, with the Sigma protease inhibitor cocktail for storage
at −80 °C until use. The purity of isolated nuclei was determined by
Western blot using anti-Nucleoporin p62 (anti-Nup62, a protein com-
plex associated with the nuclear envelope), anti-Caveolin 3 (plasma
membrane marker) and anti-Cytochrome C (marker for mitochondria).
2.11. Binding assay
Presence of PACAP binding sites in CHO-K1, HEK-293 or HeLa cells
was assessed by competitive binding assays. Cells, plated at a density
of 2.5×105 cells/well in 12-well plates, were pre-incubated in bind-
ing buffer (25 mM Tris–HCl, 5 mMMgCl2, 0.1% BSA and 5 μg/mL baci-
tracine, pH 7.4) for 10 min at room temperature. The solution was
then removed and replaced by fresh binding buffer containing 0.05
nM 125I-Ac-PACAP27 alone or in combination with either PACAP27
(10−6 M), the inactive analog [Disc6]PACAP27 [15], or TAT(48–60)
(10−6 M). Results were expressed as percentage of the speciﬁc bind-
ing of 125I-Ac-PACAP27 obtained in the presence of the inactive
ligand. [Disc6]PACAP27 was used to remove non-speciﬁc membrane-
bound radioligand.
Radioligand binding assays, using puriﬁed nuclei from various rat
tissues, were performed in an eppendorf tube containing 0.05 nM of
125I-Ac-PACAP27 and either PACAP27 (10−6 M) or [Disc6]PACAP27
(10−6 M). Binding was initiated by the addition of isolated nuclei,
and following a 2-h incubation, was stopped by rapid centrifugation
(4,000×g, 5 min). After several washes, the radioactivity was quanti-
ﬁed using a γ-counter and results were expressed as percentage of
the speciﬁc binding of 125I-Ac-PACAP27 obtained in the presence of
[Disc6]PACAP27. Data were analyzed using a non-linear curve-ﬁtting
program (Prism 4.0, GraphPad Software).
2.12. Transcription initiation assay on isolated rat testis nuclei
Transcription initiation was evaluated on freshly isolated rat testis
nuclei. Brieﬂy, nuclei were incubated at 30 °C for 30 min with
PACAP38 (from 10−10 M to 10−6 M), PACAP27 (10−7 M) or VIP
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Fig. 1. Inhibition of 125I-Ac-PACAP27 binding in CHO-K1 cells with TAT(48–60)
(10−6 M), [Disc6]PACAP27 (10−6 M) or PACAP27 (10−6 M), respectively. Data are
expressed as a percentage of bound 125I-Ac-PACAP27 in the absence of a competitive
ligand.
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6 mMMgCl2, 0.15 M KCl, 1 mM MnCl2 and 2 mM DTT. Prior to incuba-
tion with agonists, 1 μCi of [32P]-labeled uracil (3,000 Ci/mmol) and
1 mM adenine were added (guanine and cytosine were omitted to pre-
vent RNA chain elongation). Following nuclear lysis with 10 mM Tris–
HCl (pH 8), 10 mM EDTA and 1% SDS, nucleic acids were extracted
using a phenol/chloroform/isoamyl alcohol (25:24:1) solution, precipi-
tated overnight in alcohol at−20 °C, and then re-suspended in water.
Concentration was estimated based on UV absorbance at 260 nm
and the radioactivity counted using a Packard TriCarb 2100TR Liquid
Scintillation Analyzer. In a second set of experiments, isolated nuclei
were pre-treated at room temperature with PACAP(6–38) (10−6 M)
for 15 min before addition of [32P]-labeled uracil and stimulation with
PACAP38 (10−7 M).
2.13. Calcium mobilization assay on isolated rat testis nuclei
Freshly isolated rat testis nuclei were washed once with PBS con-
taining 1.5% FBS (FACS buffer) and then stained in FACS buffer with
0.5 μg/mL PI, 10 μM pluronic acid, 3 μM Fluo-4 and 6 μM Fura-Red
for 30 min at 37 °C. After washing twice by centrifugation, stained
nuclei were re-suspended in FACS buffer. Nuclei, at a rate of 450
nuclei/s, were ﬁrst examined without stimulation for 45 s, and then
PACAP38 was added and the acquisition pursued for a total of 255 s
before adding Triton (5% v/v) for another 45 s in order to reach the
maximum level of Ca2+ in the nucleoplasm. Calcium response was
recorded in real time for 300 s on PI-positive gated events using a
FACSCalibur ﬂow cytometer (BD Biosciences, San Jose, CA, USA).
After acquisition, the ﬂuorescence ratio of Fluo-4 (FL1)/FuraRed
(FL2) was computed for each sample, using Refresh Ratio 4.0 and
FlowJo programs (TreeStar, San Carlos, CA) and plotted as FL1/FL2
over time.
2.14. Statistical analysis
Results are mean±S.E.M. of at least 4 independent experiments.
pIC50, pEC50 and maximal efﬁcacy were calculated using a non-
linear least-square regression obtained with the Prism 4.0 software.
One-way ANOVA with a Dunnett's post-test was carried out to iden-
tify signiﬁcant differences between results.
3. Results
3.1. Both PACAP isoforms cross the plasma membrane of various cell
types
First, the presence of PACAP receptors was investigated in living
CHO-K1 cells to determine to which extent receptor-mediated endo-
cytosis could contribute to the putative PACAP cellular uptake. Using
competitive binding assays, no signiﬁcant differences in displacement
were observed when TAT(48–60), PACAP27 or the inactive analog
[Disc6]PACAP27 were used, indicating that the small variations in
bound 125I-Ac-PACAP27 are most likely related to non-speciﬁc inter-
actions (Fig. 1). Similar results were also observed in live HEK-293
and HeLa cells (data not shown). These results reveal that VIP/
PACAP receptors are not present, or at a very low density, on the plas-
ma membrane of these cell types. In order to avoid an artefactual re-
distribution of the membrane bound peptides into the cytoplasm and
nucleus caused by the ﬁxation step [16], FITC-labeled peptide uptake
evaluation was performed in living cells. Results, with CHO-K1 cells,
demonstrated that both PACAP isoforms, PACAP27 and PACAP38,
were not only present in the cytoplasm but also in the nucleus
(Fig. 2A and S1, CHO-K1 cells as representative). Similar distribution
was also observed in HEK-293 and HeLa cells (Fig. S2) providing evi-
dence that the peptides can enter into different cell types. Surprising-
ly, the highly basic segment PACAP(28–38) showed no cell-penetrating property (Fig. 2A, B and C). This observation could be
explained by a disordered secondary structure of this segment as ob-
served by circular dichroism analysis (Fig. S3). Thus, in further exper-
iments, PACAP(28–38) was used as negative control. Uptake efﬁcacy
of FITC-labeled peptides, evaluated by ﬂow cytometry, showed that
PACAP27 (MFI: 123±16, arbitrary units) can penetrate into cells
with an efﬁciency comparable to TAT(48–60) (MFI: 119±11)
(Fig. 2B and C). Interestingly, PACAP38-associated ﬂuorescence was
3-times higher than for PACAP27 (MFI: 385±29 versus 123±16, re-
spectively) (Fig. 2C). In fact, both PACAP isoforms were taken up in a
concentration-dependent manner, but PACAP38 ﬂuorescent signal
was always signiﬁcantly higher than its 27-amino acid counterpart
(Fig. 2D). This phenomenon was not limited to CHO-K1 cells even
though the mean ﬂuorescence intensity was lower for HEK-293 and
HeLa cells (Fig. 2E). Since these FITC-labeled peptides were chemical-
ly synthesized and puriﬁed to ensure that each peptide was covalent-
ly bound to only one FITC moiety (Table 1S), a difference in intrinsic
ﬂuorescence between PACAP isoforms cannot account for the distinct
ﬂuorescent uptake observed. Thus, these results suggest that both
isoforms can enter into different cell types but their efﬁcacy may
vary depending on the composition of the plasma membrane or cell
size (Fig. 2E). Besides, time-dependent experiments demonstrated
the propensity of both FITC-labeled peptides to quickly translocate
within the internal cell compartment since 20% of the intracellular
ﬂuorescence observed after 1 h was reached after only 2 min
(Fig. 3A). Similar observations were also found using iodinated
PACAP derivatives excepted that a plateau was reached after about
20 min (Fig. 3B). Since these two time-dependent experiments were
performed with different peptide concentrations (1 μM for FITC-
labeled peptides and 0.05 nM for iodinated peptide derivatives), it
could imply that at higher concentration the equilibrium state takes
longer to attain. Interestingly, we observed that at physiological con-
centration, PACAP38 could enter signiﬁcantly faster into cells
(Ki=0.013±0.012 at 0.05 nM vs Ki=0.042±0.010 at 1 μM)whereas
the uptake rate of PACAP27 seemed to be independent of peptide
concentration. This observation might be explained by the electro-
static interaction of the C-terminal 28–38 fragment to the plasma
membrane that favours the ﬁrst step of cellular uptake and possibly
inﬂuences the uptake mechanism [17].
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Fig. 2. (A) Distribution of FITC-conjugated PACAP(28–38), TAT(48–60), PACAP27, and PACAP38 in living untransfected CHO-K1 cells as observed by confocal microscopy. Nuclei
were stained with DRAQ5™. (B) and (C) Transduction efﬁciency of FITC-labeled peptides in CHO-K1 cells. Cells were incubated for 1 h with ﬂuorescent peptides (10−6 M) before
FACS analysis. (D) Effect of extracellular peptide concentration on cellular uptake. CHO-K1 cells were incubated with various concentrations of ﬂuorescent peptides ranging from
10−9 to 10−6 M. (E) Evaluation of FITC-labeled PACAP cellular uptake in various cell lines including CHO-K1, HEK-293 and HeLa cells. Data were collected using WinMDI software.
Signiﬁcant differences (**pb0.01) were determined by one-way ANOVA followed by a Dunnett's post-test.
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Confocal microscopy and ﬂow cytometry analysis showed that the
cellular uptake of FITC-labeled [Disc6]PACAP27, an inactive PACAP an-
alog that does not bind to the receptors [15], into living CHO-K1 cells
was similar to that of FITC-labeled PACAP27. Similar observations
were also observed with HEK-293 or HeLa cells. These results provide
evidence that PACAP38 and PACAP27 cellular uptake, observed in
these cell lines, is not a receptor-mediated event (Fig. 4A and B).
Experiments were then performed in order to determine the propen-
sity of PACAP isoforms to form pores within the cellular membrane.
Analysis of cells, treated with ﬂuorescent PACAP27 or PACAP38
(10−6 to 10−5 M) and stained with propidium iodide (PI), revealed
that less than 1% of the cells were PI positive (data not shown) sug-
gesting that the integrity of the cell membrane was preserved. In
addition, no change in the viability of CHO-K1 cells was observed fol-
lowing their incubation with high concentrations of either PACAP27
or PACAP38 for 4 h (10−6 to 10−5 M) (Fig. S4). Overall, these results
conﬁrmed that PACAP isoforms (1) do not disrupt the membrane,
(2) are non toxic and (3) can enter into cells by a complementary
receptor-independent mechanism.
Deciphering the cellular entry mechanism was also achieved by
evaluating whether uptake is temperature- and/or energy-dependent.
When incubated at 4 °C or in the presence of an ATP-depletor, i.e.sodium azide and 2-deoxy-D-glucose, both isoforms were still able to
translocate within the internal compartment of living CHO-K1 cells.
However, the cellular uptake, as observed by ﬂow cytometry analysis
(Fig. 5A) and confocal microscopy (Fig. S5), was signiﬁcantly reduced
by up to 80%. Similarly, at physiological concentration (0.05 nM), a
substantial reduction of the cellular uptake of 125I-Ac-PACAP27 and
125I-Ac-PACAP38 was observed at low temperature (Fig. S6). These re-
sults support the involvement of direct translocation and endocytosis
in the cellular uptake of PACAP isoforms.
In order to investigate the possible involvement of different endo-
cytic pathways in the cellular uptake of PACAP isoforms, several
classical inhibitors of endocytosis were used. As shown in Fig. 5B,
treatment of cells with the caveolae-dependent endocytosis inhibitor
nystatin or depletion of plasma membrane cholesterol by MβCD did
not signiﬁcantly change the peptide cellular uptake. As a conse-
quence, the caveolae-mediated endocytosis that is characterized by
plasma membrane invaginations formed from cholesterol and
sphingolipid-rich microdomains, or lipid rafts, does not appear to be
the main internalization mechanism. The role of intracellular pH in
the internalization process was also studied using two weak bases,
NH4Cl and chloroquine, as neutralizing agents. For both peptides, no
signiﬁcant variation of cellular uptake was observed with these
agents. Interestingly, after incubation with PACAP38 ﬂuorescent iso-
form, cells pre-incubated with NH4Cl, a weak base that increase the
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punctuated ﬂuorescence that might reﬂect the ability of PACAP38 to
escape from the endosomal/lysosomal compartments (Fig. S7). Block-
age of plasma membrane protein thiol functional groups with malei-
mide had no noticeable impact on PACAP cellular uptake. However,
under a hypertonic sucrose environment, known to prevent assembly
of clathrin-coated pits or their pinching off the plasmamembrane, the
uptake of PACAP27 and PACAP38 was decreased by about 40% in
comparison to control. Similarly, by preventing the recycling of cla-
thrin and thus hindering endocytosis through clathrin-dependent
mechanisms with the cationic amphiphilic drug chlorpromazine, a
signiﬁcant decrease in cellular uptake of both PACAP isoforms was
observed. These results suggest that the internalization of PACAPs in-
volves the clathrin-dependent pathway. Interestingly, the uptake of
PACAP38 was not affected by nocodazole, a microtubule-disrupting
agent, whereas a 40% reduction in cellular uptake of PACAP27 was ob-
served in the same conditions. These observations were also con-
ﬁrmed by confocal microscopy (data not shown). Altogether, these
results suggest differential endocytosis mechanisms for PACAP27
and PACAP38 that could be related to the C-terminal highly basic do-
main of PACAP38. Finally, pre-treatment with amiloride, a commonly
used macropinocytosis inhibitor, caused a marked reduction in cellu-
lar uptake of both PACAP isoforms indicating that the cellular uptake
of these peptides is also dependent of the macropinocytosis pathway.
3.3. Exit of PACAP isoforms from the cytosol
As described earlier, internalization of 125I-labeled PACAP iso-
forms reaches a plateau most probably when equilibrium between
extracellular and intracellular peptide concentration is established.Attainment of this state suggests that both peptides could also pos-
sess the ability to exit the cells by crossing the plasma membrane.
To test this possibility, cells were ﬁrst incubated with 125I-Ac-
PACAP27 or 125I-Ac-PACAP38, and following removal of the media
and addition of fresh buffer, kinetics of radioactive material exiting
the intracellular compartment was determined by measuring the ra-
dioactivity in culture medium over various periods of time (Fig. 6A).
As shown, the percentage of cytosolic radioactive species in cells de-
creased with time. A similar phenomenon was also observed by
ﬂow cytometry with a decrease of cellular ﬂuorescence in living
CHO-K1 cells (Fig. 6B). Next, the nature of the materials exiting the cy-
tosol was investigated. Indeed, enzymatic breakdown of intracellular
peptides could eventually generate radioactive orﬂuorescent fragments
that could have the ability to leave the cells by diffusion through the
plasma membrane. MS and RP-HPLC analysis of peptide species exiting
PACAP38-loaded cells showed the presence of intact PACAP38 as the
main peptide species (Fig. S8), as well as 13 other fragments including
PACAP27 (Table 1). These data indicate that even though the neuropep-
tide can be degraded into the cytoplasm, a non negligible amount of
PACAP38 but also PACAP27 can exit the cells in order to activate neigh-
boring cells in an autocrine or paracrine manner.
3.4. Presence of PACAP binding sites in rat tissue nuclei
The occurrence of PACAP nuclear binding sites was evaluated in
ﬁve different nuclear extracts from rat brain, spleen, adrenal gland,
kidney and testis. Each tested tissue was already reported to express
PACAP receptors at their cellular membrane [3]. Purity of these prep-
arations was assessed by Western blotting, using known subcellular
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plexes), cytochrome C (protein associated with the inner membrane
of mitochondria), and caveolin-3 (protein forming membrane caveo-
lae). The absence of cavelolin-3 and cytochrome C immunoreactivity
conﬁrmed the high purity of these nuclear extracts (Fig. 7A). Binding
experiments were then used to further evaluate the presence of
PACAP binding sites (Fig. 7B). Non-speciﬁc binding was thought to re-
ﬂect interaction of PACAP with the nuclear membrane but also the ac-
cumulation of PACAP within the nuclei. As such, all experiments were
performed in the presence of an inactive analog of PACAP27 with simi-
lar structural and physicochemical properties, i.e. [Disc6]PACAP27 that
is unable to bond PACAP receptors, in order to displace non-speciﬁc in-
teractions. Treatment of the preparation with [Disc6]PACAP27 or
PACAP27 was thus considered to represent speciﬁc displacements.
With the exception of kidney nuclear extracts, PACAP27 was able to sig-
niﬁcantly displace the radioligand from putative nuclear binding sites
(Fig. 7B). Altogether, these observations show the presence of speciﬁc
PACAP binding sites at the nuclear membrane and suggest the non-
ubiquitous pattern of such localization.
3.5. PACAP stimulates calcium release and transcription initiation in rat
testis nuclei
Using isolated testis nuclei incubated in calcium free mediumwith
a Fluo-4/Fura-red indicator mixture, an increase of the FL-1/FL-2 ratio
was noticed following the addition of PACAP38 (10−7 M) (Fig. 8A).
Interestingly, a signiﬁcant release of intranuclear calcium was still
observed at 10−9 M (data not shown), suggesting a dose-dependent
effect of PACAP on calcium release. Mobilization of intranuclearcalcium is often associated with the regulation of transcription. The
effect of PACAP on de novo RNA synthesis was thus investigated
using freshly isolated and puriﬁed testis nuclei. As shown, both
PACAP isoforms were able to stimulate transcription initiation
(Fig. 8B). Interestingly, pre-incubation of rat testis nuclei with
PACAP(6–38), a reported PAC1 receptor antagonist [18], completely
abolished PACAP38-associated transcription initiation whereas VIP,
known to bind and activate VPAC1 and VPAC2 but not PAC1 recep-
tors, was unable to stimulate transcription (Fig. 8B). This effect,
which was found to be dose-dependent, was already noticeable at a
subnanomolar concentration of PACAP38 (10−10 M) (Fig. 8C). Alto-
gether, these results suggest that the receptor present at the nuclear
membrane is functional, as demonstrated by calcium mobilization
assay and transcription initiation, and might be related to PAC1
receptors.
4. Discussion
Receptor-mediated endocytosis is generally related to the regula-
tion of transmembrane signal transduction. Through interaction of its
cognate ligand, the activated receptor internalizes and is transported
to late endosomes and lysosomes for degradation. However, this phe-
nomenon is also actively implicated in transducing signals from the
cell periphery to the nucleus. Presence of functional GPCRs at the nu-
clear membrane has raised questions regarding how their ligand
might reach their intracellular target. Apart from a direct intracellular
production as already demonstrated for PACAP [19] and escape of the
natural ligand from endocytic/lysosomal vesicles, propensity of various
Table 1
MS analysis of the excreted peptide species.
No Observed mass(Da) Corresponding sequence Calculated mass (Da)
1            5            10 15 20              25             30              35
1 4536.67 HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK 4535.28
2 4408.19 HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKN 4407.11
3 4065.97 HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQR 4065.70
4 3492.51 HSDGIFTDSYSRYRKQMAVKKYLAAVLGKR 3490.03
5 3336.53 HSDGIFTDSYSRYRKQMAVKKYLAAVLGK 3333.85
6 3169.71 HSDGIFTDSYSRYRKQMAVKKYLAAVL +Na+ 3148.62
7 2519.89 HSDGIFTDSYSRYRKQMAVKK 2517.84
8 2262.38 HSDGIFTDSYSRYRKQMAV 2261.49
9 2165.59 HSDGIFTDSYSRYRKQMA 2162.36
10 1386.55 HSDGIFTDSYSR* 1384.42
11 2036.81 YLAAVLGKRYKQRVKNK + Na+ 2039.44
12 1352.66 KRYKQRVKNK + Na+ 1351.61
13 1331.34 KRYKQRVKNK 1329.61
14 1096.90 RYKQRVKN   + Na+ 1095.36
15 916.62 YKQRVKN    +  Na+ 917.08
* trace amount detected.
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independent manner has been poorly investigated. In this paper, we
demonstrate for the ﬁrst time that both PACAP isoforms are able to
cross the cellular membrane by a complementary receptor-independent
mechanism.
The ﬁrst evidence that PACAP may be able to cross the plasma
membrane arose from the proposed two-step ligand transportation
model for PACAP [20]. In this model, the peptide initiates a non spe-
ciﬁc interaction with cell membranes, and then undergoes a two-
dimensional diffusion on the membrane surface that leads to speciﬁc
binding to its membrane receptors that will ultimately trigger their
activation and their desensitization [20]. More than 10 years ago,
PAC1 receptor internalization upon ligand binding was described as
a process not involving classical signaling cascade activation, such as
adenylyl cyclase or phospholipase C signaling [21]. Indeed, internali-
zation of 125I-PACAP27, using a receptor mutant unable to trigger an
adenylyl cyclase or phospholipase C response, was only reduced by
about 25% when compared to wild type. Since PACAP isoforms are
both able to quickly cross the plasma membrane at physiological con-
centration (Fig. 2B and Fig. S2) in a receptor-independent manner
(Fig. 3), it is conceivable that the apparent intracellular radioactivity
measured in this experiment might be due, at least in part, to
PACAP cellular uptake. Noteworthy, the present study provides new
highlights regarding the role of the C-terminal 28–38 segment of
PACAP38. The signiﬁcant uptake difference observed between
PACAP38 and PACAP27 could indicate a role for this 28–38 segment
in the translocation process through plasma membrane that could
impact on downstream stimulation of membrane or intracellular
PACAP receptors.
Cationic CPPs uptake does not rely on a unique entry mechanism
but rather depends on process involving multiple pathways [22]. In-
deed, translocation may occur either through the lipid bilayer (by
forming pores, inverted micelles or diffusion) or the endocytotic
internalization. In this study, we demonstrated that both PACAP iso-
forms translocate into living cells at 4 °C or in the presence of ATP-
depletor (Fig. 4A) suggesting the involvement of direct translocation.
Peptide diffusion has been considered as improbable because this
process requires high energy of desolvation [23]. Flow cytometry
analysis of cells treated with ﬂuorescent analogs revealed that less
than 1% of the cell population was PI positive suggesting that pores
formation might not be involved in the translocation of these pep-
tides into cells. Therefore, the “inverted micelle” might represent a
possible internalization mechanism of PACAP isoforms. Supporting
this hypothesis, it was demonstrated that PACAP isoforms adopted
an amphipathic helical conformation when interacting with cellularmembrane [10,24]. Thus, this ﬁrst contact is favoured by electrostatic
interaction between the positively charged residues of PACAP and the
negatively charged components of the lipid membrane. In turn, in in-
teraction with the hydrophobic part of the membrane, the hydropho-
bic side (Phe6, Tyr10, Leu13, and Met17) could form a micelle-binding
interface inserted into the hydrophobic interior of the membrane
[10]. As demonstrated, endocytosis seems to be also involved in the
uptake mechanism of PACAP isoforms. Indeed, we showed that
clathrin-dependent endocytosis and macropinocytosis may be in-
volved in the internalization of PACAPs since the uptake of ﬂuores-
cent PACAP isoforms were signiﬁcantly reduced in cells pretreated
with hypertonic sucrose, chlorpromazine, nocodazole and amiloride.
Thus, both energy-dependent (via clathrin-coated endocytosis and
macropinocytosis) and energy-independent (occurring at 4 °C or
with ATP-depletion cells) pathways might mediate PACAP penetra-
tion across the plasma membrane.
In the continuity of previous works [7–9], evidence for the presence
of PACAPbinding sites in the nuclear/perinuclear environmentwas pro-
vided. In particular, PACAP nuclear binding sites were clearly observed
in rat tissues such as brain, testis, spleen and adrenal gland. Moreover,
these receptors should be functional and possibly involved in gene
regulation since calcium mobilization and transcription initiation
were demonstrated on isolated rat testis nuclei. As abovementioned,
receptor-mediated endocytosis could be perceived as a possible way
for PACAP to reach these putative binding sites (Fig. S9). However, the
ability of PACAP to dissociate from its ligand–receptor complex and
thus exit the endocytotic vesicles, is still unknown. In addition, it was
shown that the dissociation of 125I-PACAP27 from the ligand–receptor
complex was slow and incomplete [25]. In this study, we observed
that at physiological concentration the neuropeptide quickly translo-
cates into cells via direct translocation (at least in part) that would di-
rectly release PACAP to the cytosol. The fact that PACAP isoforms also
enter cells by a direct translocation at physiological concentration sug-
gests that these peptides might be available to interact with intracellu-
lar endogenous receptors and that this process could be involved in the
control of cellular events. In addition, the observation of endocytic ves-
icles (Fig. S7) in living CHO-K1 cells pretreated with NH4Cl and chloro-
quine suggest that PACAP could be released from endosomes and
macropinosomes into the cytosol. Correlated to the propensity of
PACAP isoforms to reach the internal cell compartment, these results
suggest an intracrine role for PACAP that is supported, at least in the tes-
tis, by the existence of a PACAP precursor with no signal peptide [19].
Complementing this perspective, the observation that intact PACAP
peptideswere able to exit the intracellular compartment raised the pos-
sibility that PACAP is able to trigger a self-sustainable loop leading to
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could represent an explanation regarding the subnanomolar activity
of PACAP observed in various in vitro and in vivo models [3,26,27]. Al-
though it is clearly established that PACAP is able to act as a paracrine
and autocrine regulatory factor [3,28], this study complements the
intracrine pharmacology of PACAP by demonstrating its ability to
cross the plasma membrane in order to activate intracellular receptors
and its ability to exit the cytosol creating a potential sustainable loop.
As previously reported, nuclear GPCRs activation can be caused by
different signalling pathways than those associated to the membrane
system, as demonstrated for the renin–angiotensin system [29], estro-
gen receptor GPR30 [30], and the metabotropic glutamate receptor 5
[31]. Besides, these receptors are often able to stimulate nuclear calcium
release and therefore are usually associated with gene expression as
exempliﬁed with nuclear endothelin, angiotensin, and beta-adrenergic
receptors [32–34]. As demonstrated in this study, nuclear PAC1-
receptors appear to be associated to calcium release and transcription
initiation complementing an initial report observing the stimulation
of the MAPK, ERK by PACAP in enriched cytosolic fractions through a
PAC1 like protein [7]. The speciﬁc role of such an intracellular systemhas not been investigated but could involve neuroprotective effects
(via MAPK activation), steroid hormone secretion in adrenal gland
(via stimulation of cAMP, inositol phosphate production and calcium
mobilization), regulation of cytokines (via cAMP-dependent pathway)
and stimulation of progesterone and testosterone production (via acti-
vation of adenylyl cyclase and phospholipase C) [3,35,36]. Supporting
this hypothesis, numerous signalling messengers have been identiﬁed
in isolated cell nuclei including the abovementioned signalling mole-
cules [8,33,37]. Altogether, these observations suggest that intracellular
PACAP receptors could play a major or complementary role in PACAP-
associated activities. Although this assertionwill need further investiga-
tion, such intracellular PACAPergic system should be taken into account
to explain PACAP physiological and pathophysiological actions as well
as during drug development.
In conclusion, we demonstrated for the ﬁrst time the propensity of
PACAP isoforms to reach the intimal cellular space in a receptor-
949N.-D. Doan et al. / Biochimica et Biophysica Acta 1823 (2012) 940–949independent manner in order to activate its cytosolic and nuclear
binding sites. These cell-penetrating properties of the neuropeptide
PACAP have never been reported and might explain in part the
subnanomolar activities often associated with PACAP. Although the
physiological role of intracellular PACAP receptors remains to be in-
vestigated, our ﬁndings suggest that this intracellular GPCR could be
associated with speciﬁc biological activities that should be taken
into account during the development of PACAP-based drugs. Finally,
our study opens up new avenues for the use of PACAP or its deriva-
tives as potent CPPs for the delivery of therapeutically relevant agents
and classiﬁes this neuropeptide as a novel endogenous CPP.
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